Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The site’s displayed revision identifier changed from v3.8.0 to v3.8.1.
    Difference
    0.1%
    Check dated 2026-11-22T14:15:26.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    The study record for pembrolizumab plus fulvestrant in advanced breast cancer is displayed, including eligibility criteria, study locations, treatment details, and outcome measures.
    Difference
    50%
    Check dated 2026-11-08T13:51:30.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:10:45.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology across NIH content.
    Difference
    1%
    Check dated 2026-10-25T14:08:11.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T14:42:55.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.0 to v3.7.1 while the study page continued to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T15:15:39.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.